CONTINUATION OF OXALIPLATIN IS A POTENTIAL PREDICTIVE FACTOR IN ADJUVANT FOLFOX FOR STAGE IIIB OR IV COLORECTAL CANCER

被引：0
|
作者：
Suenaga, Mitsukuni
Mizunuma, Nobuyuki
Shinozaki, Eiji
Matsusaka, Satoshi
Chin, Keisho
Kuboki, Yasutoshi
Watanabe, Toshiyasu
Fujimoto, Yoshiya
Ueno, Masashi
Kuroyanagi, Hiroya
Oya, Masatoshi
Yamamoto, Noriko
Hatake, Kiyohiko
机构：
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [1] Necessity of oxaliplatin in adjuvant chemotherapy for stage IIIb colorectal cancer
    Sonoda, Hiromichi
    Shimizu, Tomoharu
    Miyake, Toru
    Takebayashi, Katsushi
    Kaida, Sachiko
    Kawai, Yuki
    Sonoda, Ayano
    Inatomi, Osamu
    Murata, Satoshi
    Tani, Masaji
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
    Bruno Vincenzi
    Anna Maria Frezza
    Gaia Schiavon
    Chiara Spoto
    Raffaele Addeo
    Vincenzo Catalano
    Francesco Graziano
    Daniele Santini
    Giuseppe Tonini
    Supportive Care in Cancer, 2013, 21 : 1313 - 1319
  • [3] Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
    Vincenzi, Bruno
    Frezza, Anna Maria
    Schiavon, Gaia
    Spoto, Chiara
    Addeo, Raffaele
    Catalano, Vincenzo
    Graziano, Francesco
    Santini, Daniele
    Tonini, Giuseppe
    SUPPORTIVE CARE IN CANCER, 2013, 21 (05) : 1313 - 1319
  • [4] Erratum to: Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
    Bruno Vincenzi
    Anna Maria Frezza
    Gaia Schiavon
    Chiara Spoto
    Nicola Silvestris
    Raffaele Addeo
    Vincenzo Catalano
    Francesco Graziano
    Daniele Santini
    Giuseppe Tonini
    Supportive Care in Cancer, 2013, 21 (4) : 1209 - 1209
  • [5] Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant FOLFOX IV.
    Frezza, Anna Maria
    Schiavon, Gaia
    Vincenzi, Bruno
    Addeo, Raffaele
    Catalano, Vincenzo
    Graziano, Francesco
    Santini, Daniele
    Tonini, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] SAFETY OF ADJUVANT FOLFOX FOR JAPANESE PATIENTS WITH STAGE III/IV COLORECTAL CANCER FOLLOWING CURATIVE RESECTION
    Kawamoto, Yasuyuki
    Yoshino, Takayuki
    Fukushima, Hiraku
    Hara, Hiroki
    Kojima, Takashi
    Oono, Yasuhiro
    Fuse, Nozomu
    Ikematsu, Hiroaki
    Yano, Tomonori
    Minashi, Keiko
    Tahara, Makoto
    Kaneko, Kazuhiro
    Doi, Toshihiko
    Ohtsu, Atsushi
    ANNALS OF ONCOLOGY, 2010, 21 : 15 - 15
  • [7] Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy
    Zimmermann, Maike
    Li, Tao
    Semrad, Thomas J.
    Wu, Chun-Yi
    Yu, Aiming
    Cimino, George
    Malfatti, Michael
    Haack, Kurt
    Turteltaub, Kenneth W.
    Pan, Chong-xian
    Cho, May
    Kim, Edward J.
    Henderson, Paul T.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (04) : 1070 - 1079
  • [8] Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
    Park, Dawon
    Baek, Se-Jin
    Kwak, Jung-Myun
    Kim, Jin
    Kim, Seon-Hahn
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2018, 94 (04) : 196 - 202
  • [9] Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?
    Esch, Anouk
    Coriat, Romain
    Perkins, Geraldine
    Brezault, Catherine
    Chaussade, Stanislas
    PRESSE MEDICALE, 2012, 41 (01): : 51 - 57
  • [10] FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer
    Grothey, A
    Sargent, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3311 - 3313
12345